Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GCK | P35557 | 15/20 | 0.47 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178326 | 0.87 | GCK (0.52) | GCKRARARARBRARG | |
| SCHEMBL1107734 | 0.85 | GCK (0.57) | GCKRARARARBRARG | |
| SCHEMBL3855078 | 0.84 | CYP2C9 (0.54) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL12408474 | 0.83 | GCK (0.50) | GCKRARARARBRARG | |
| SCHEMBL3605375 | 0.82 | GCK (0.49) | GCKRARARARBRARG | |
| SCHEMBL1107709 | 0.81 | GCK (0.55) | GCKRARARARBRARG | |
| SCHEMBL1107706 | 0.81 | GCK (0.63) | GCKRARARARBRARG | |
| SCHEMBL2175603 | 0.81 | GCK (0.47) | GCKRARARARBCA12CA1 | |
| SCHEMBL3855641 | 0.80 | CYP2C9 (0.53) | CYP2C9CYP2C19CA12CA1CA2 | |
| SCHEMBL2654383 | 0.80 | GCK (0.50) | GCKRARARARBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-07-12 | — | — | US | disclosed |
| WO-2011081280-A2 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178765-A1 | NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF | GCK, GCKR, HK1 | CYP2C9 2499/4885CYP2C19 2244/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.